冬斯说明书
冬斯说明书
技术参数垒块类型403 405/407 410/412 415最大供给压强200毫巴（20千帕）360毫巴（36千帕）IP等级IP54外界温度外界温度－15℃至＋70℃电磁阀DIN EN 161，A类，2组电压/频率～（AC）50-60Hz220-230V－15%至＋10%～（AC）50-60Hz230V－15%至＋10%功率/需求24V A～（AC）230V20℃28VA～（AC）230V20℃50VA～（AC）230V20℃50V A～（AC）230V20℃除尘装置过滤器网眼规格为0.8mm,不许移动气体吸发装置即可更换过滤器组件部署图右失（刃）垒块由以下部分组成1-法兰1-过滤器2-气体压强测试点1-气体压强开关3-法兰固定螺丝1-压强稳定器4-阻尼器调整装置2-电磁阀5-制动器调整装置-可快速打开安全阀6-输出装置螺母-缓慢打开调整阀7-用于螺母固定螺钉（未密封）图1. 8-低气压开关MB DLE 405-407-410-412-415 B01 S20 MB DLE 403 B01 S20非必需情况下需移动六角栓，请根据第3页指示操作。
气体吸收装置组装气体吸收装置必需在燃烧器左侧安装，如安装需在右侧进行时，有必需将另一侧压强测试点移动。
(2)对于型号MB DLE 403 B01，有必需移动气压开关位置。
（8）如气体吸收器直径和燃烧器直径不一致，就需要在二者之间安装转换器气体供给管道和气体吸收器之间连接，经过使用气体吸收器法兰和将其固定起来螺母实现（3）最好使用十字头螺钉在任何情况下，安装阀时候线圈不能处于朝地一面，当完成安装后，必需检验是否存在漏气并确保气体吸收器正常工作。
压强稳定器调整（4）使用适宜螺丝起子来固定压强调整器：顺时针方向位拧紧，逆时针方向为松开。
当压强阀安装达成理想效果后，盖上盖子并将电线末端用铅封好，使穿过孔间线圈尽可能短。
阀调整缓慢点火输出（阀初始开启相位）调整：再打开外壳（5）并根据+/—方向旋转螺钉以后进行翻转外壳（5）能够作为调整工具。
冬斯电磁阀参数说明
冬斯电磁阀参数说明全文共四篇示例，供读者参考第一篇示例：冬斯电磁阀参数说明冬斯电磁阀是一种常用的控制元件，在工业自动化领域广泛应用。
它通过电磁力来控制阀门的开启和关闭，从而实现流体的控制。
在选择使用冬斯电磁阀时，了解其参数是非常重要的。
下面将详细介绍冬斯电磁阀的参数说明。
1. 电压范围：冬斯电磁阀一般适用于直流电压或交流电压，通常电压范围在12V至240V之间。
在选择电磁阀时，需根据实际情况选取合适的电压范围。
2. 通径大小：通径大小是指电磁阀进出口的口径大小，通常以英寸或毫米为单位。
通径大小决定了电磁阀适用的流体流量大小，通常通径越大，流量也就越大。
3. 工作压力：工作压力是指电磁阀能够承受的最大压力，通常以MPa或bar为单位。
在选择电磁阀时，需根据工作介质的压力选择适合的工作压力范围。
5. 寿命参数：寿命参数是指电磁阀的使用寿命，通常以次数或时间为单位。
一般来说，电磁阀的寿命与其制造质量和使用环境有关，因此在选择电磁阀时，需考虑其寿命参数。
6. 控制方式：控制方式是指电磁阀的开启和关闭方式，常见的控制方式有直接式、间接式和脉冲式等。
在选择电磁阀时，需根据控制方式来确定适合的电磁阀。
以上是关于冬斯电磁阀的参数说明，希望对大家选择和使用电磁阀有所帮助。
冬斯电磁阀是一种常用的控制元件，具有广泛的应用领域，我们可以根据实际需要选择不同参数的电磁阀，以满足不同的控制需求。
通过了解和掌握电磁阀的参数，可以更加准确地选择合适的电磁阀，从而确保系统的稳定运行。
希望本文能够为大家提供一些参考，谢谢阅读！第二篇示例：冬斯电磁阀参数说明冬斯电磁阀是一种常见的控制装置，广泛应用于工业、农业、生活等各个领域。
它通过控制电磁铁的电流来控制阀门的开启和关闭，从而实现流体的控制。
在选择和应用冬斯电磁阀时，了解其参数是至关重要的。
下面我们将详细介绍冬斯电磁阀的各项参数。
1. 阀体材质：冬斯电磁阀的阀体通常采用优质的不锈钢材质制成，具有耐腐蚀、耐高温、抗压能力强的特点，适用于各种恶劣环境下的使用。
Viltepso (Viltolarsen) 使用说明说明书
UnitedHealthcare ® Community PlanViltepso ® (Viltolarsen)Policy Number : CS2023D0095KEffective Date : September 1, 2023 Instructions for Use Table of Contents Page Application ..................................................................................... 1 Coverage Rationale ....................................................................... 1 Applicable Codes .......................................................................... 2 Background ................................................................................... 2 Clinical Evidence ........................................................................... 3 U.S. Food and Drug Administration ............................................. 4 References ..................................................................................... 4 Policy History/Revision Information ............................................. 5 Instructions for Use ....................................................................... 5 This Medical Benefit Drug Policy does not apply to the states listed below; refer to the state-specific policy/guideline, if noted: State Policy/Guideline FloridaRefer to the state’s Medicaid clinical policy KansasNone LouisianaRefer to the state’s Medicaid clinical policy New JerseyViltepso ® (Viltolarsen) (for New Jersey Only) North CarolinaNone OhioViltepso ® (Viltolarsen) (for Ohio Only) PennsylvaniaViltepso ® (Viltolarsen) (for Pennsylvania Only) TexasRefer to drug-specific criteria found within the Texas Medicaid Provider Procedures ManualViltepso (viltolarsen) may be covered for the treatment of Duchenne muscular dystrophy (DMD) in patients who meet all of the following criteria :• For initial therapy , all of the following:o Diagnosis of Duchenne muscular dystrophy by, or in consultation with, a neurologist with expertise in the diagnosis of DMD; and o Submission of medical records (e.g., chart notes, laboratory values) confirming the mutation of the DMD gene is amenable to exon 53 skipping; ando One of the following: ▪ Submission of medical records (e.g., chart notes, laboratory values) confirming that the patient has a 6-MinuteWalk Test (6MWT) ≥ 300 meters while walking independently (e.g., without side-by-side assist, cane, walker,wheelchair, etc.) prior to beginning Viltepso therapy; or▪ Both of the following:Commercial Policy • Viltepso ® (Viltolarsen)Submission of medical records (e.g., chart notes) confirming that the patient is ambulatory without needing anassistive device (e.g., without side-by-side assist, cane, walker, wheelchair, etc.); and o One of the following:▪Patient has achieved a score of greater than 17 on the North Star Ambulatory Assessment (NSAA); or▪Patient has achieved a time to rise from the floor (Gower’s test) of less than 7 seconds;ando Viltepso is prescribed by, or in consultation with, a neurologist with expertise in the treatment of DMD; ando Viltepso dosing for DMD is in accordance with the United States Food and Drug Administration approved labeling; and o Viltepso is not used concomitantly with other exon skipping therapies for DMD; ando Initial authorization will be for no more than 6 monthsFor continuation of therapy, all of the following:o Patient has previously received Viltepso; ando Viltepso is prescribed by, or in consultation with, a neurologist with expertise in the treatment of DMD; ando Submission of medical records (e.g., chart notes) confirming that the patient is ambulatory without needing an assistive device (e.g., without side-by-side assist, cane, walker, wheelchair, etc.); ando Viltepso dosing for DMD is in accordance with the U.S. Food and Drug Administration (FDA) approved labeling; and o Viltepso is not used concomitantly with other exon skipping therapies for DMD; ando Reauthorization will be for no more than 12 monthsViltepso will not be covered for other forms of muscular dystrophy.The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.HCPCS Code DescriptionJ1427 Injection, viltolarsen, 10 mgDiagnosis Code DescriptionG71.01 Duchenne or Becker muscular dystrophyDuchenne muscular dystrophy (DMD) is an X-linked disease that affects 1 in 3,600-6,000 live male births. DMD occurs as a result of mutations (mainly deletions) in the dystrophin gene. These mutations lead to an absence or a defect of the protein, dystrophin, resulting in progressive muscle degeneration, leading to loss of ambulation and additional respiratory, orthopedic, and cardiac complications. If left untreated, mean age of death is approximately 19 years of age.2-4Viltolarsen is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer (PMO) subclass. PMOs are synthetic molecules in which the five-membered ribofuranosyl rings found in natural DNA and RNA are replaced by a six-membered morpholino ring. Each morpholino ring is linked through an uncharged phosphorodiamidate moiety rather than the negatively charged phosphate linkage that is present in natural DNA and RNA. Each phosphorodiamidate morpholino subunit contains one of the heterocyclic bases found in DNA (adenine, cytosine, guanine, or thymine).1Viltolarsen is designed to bind to exon 53 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping. Approximately 8% of DMD patients have out of frame deletion mutations amenable to exon 53 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein.1Eteplirsen (Exondys 51) was the first PMO approved by the U.S. Food and Drug Administration for treatment of DMD patients with confirmed genetic mutations amenable to exon 51 skipping. Approximately 13% of DMD patients have out of frame deletion mutations amenable to exon 51 skipping. This indication was approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with eteplirsen. A clinical benefit of eteplirsen has not been established. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.5Golodirsen (Vyondys 53) was the second PMO approved by the US Food and Drug Administration for treatment of DMD patients with confirmed genetic mutations amenable to exon 53 skipping, the same population as viltolarsen. Approximately8-10% of DMD patients have out of frame deletion mutations amenable to exon 53 skipping. This indication was also approved under accelerated approval based on an increase in dystrophin in skeletal muscle.6Casimersen (Amondys 45) is an antisense oligonucleotide that is designed to bind to exon 45 of dystrophin pre-messenger RNA, resulting in exon 45 skipping during messenger RNA processing in patients with amenable deletion mutations of the DMD gene. The FDA granted accelerated approval of casimersen for the treatment of patients with DMD who have a confirmed mutation of DMD that is amenable to exon 45 skipping, which is thought to cause approximately 8 percent of DMD cases.14Viltolarsen is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.1A phase II study evaluated two doses of viltolarsen in 16 ambulatory boys aged 4 to 9 years with a DMD diagnosis and DMD gene amenable to exon 53 skipping over 24 weeks. Ambulatory boys on a stable corticosteroid regimen for at least 3 months who could complete time to stand from supine, time to run/walk 10 m, and time to climb four stairs assessments were included. The study was a multicenter, two period dose-finding clinical trial. The first study period, which corresponded to the first 4 weeks of treatment following enrollment, was double-blinded and placebo-controlled. Participants in both dose cohorts were randomized 3:1 to receive viltolarsen or placebo. The second study period began at week 5 for each participant. During this period, all participants received viltolarsen according to their cohort dose for a 20-week open-label treatment. Primary study outcomes included safety, tolerability, and pharmacokinetics of low-dose (40 mg/kg per week) and high-dose (80 mg/kg per week) viltolarsen in ambulant boys with DMD. Efficacy was assessed based on change from baseline in dystrophin protein level (measured as % of the dystrophin level in healthy subjects, i.e., % of normal) at week 25. Muscle dystrophin production was assessed as protein production by Western blot for the primary study efficacy outcome and as dystrophin mRNA splicing on RT-PCR, dystrophin protein production by MS, and dystrophin localization by IF staining for secondary study efficacy outcomes. Additional secondary efficacy outcomes were gross motor skill assessments of timed function tests, including time to stand from supine, time to run/walk 10 m, time to climb four stairs, North Star Ambulatory Assessment, and 6-minute walk test as well as quantitative muscle testing. These outcomes were compared with a matched natural history control group from the Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS).In patients who received viltolarsen 80 mg/kg once weekly, mean dystrophin levels increased from 0.6% of normal at baseline to 5.9% of normal by week 25, with a mean change in dystrophin of 5.3% of normal levels (p = 0.01) as assessed by validated Western blot; the median change from baseline was 3.8%. All patients demonstrated an increase in dystrophin levels over their baseline values. As assessed by mass spectrometry, mean dystrophin levels increased from 0.6% of normal at baseline to 4.2% of normal by week 25, with a mean change in dystrophin of 3.7% of normal levels; the median change from baseline was 1.9%.Comparison of viltolarsen-treated participants with 65 age-matched and treatment matched natural history controls from CINRG DNHS suggested evidence of clinical benefit of viltolarsen treatment. Viltolarsen-treated participants showed improvement or stabilization of function over the 25-week period, whereas the CINRG DNHS external comparator group exhibited a decline in all timed function tests, except for time to climb four stairs. Velocity in the time to run/walk 10 m test significantly improved in viltolarsen-treated participants at weeks 13 and 25 compared with a decline in controls from CINRG DNHS (change at 25 weeks compared with baseline: viltolarsen, 0.23 m/s; control, −0.04m/s). The 6-minute walk test showed significant improvement at week 25 in viltolarsen treated participants, whereas results from CINRG DNHS controls declined over the same period (change at 25 weeks compared with baseline: viltolarsen, 28.9 m; control, −65.3 m). Significant improvements in time to stand from supine were observed (change at 25 weeks compared with baseline: viltolarsen, −0.19 s; control, 0.66 s). Velocity in the time toimprovement or stabilization, but the differences between viltolarsen treatment and external comparator controls were not significant. Measures of muscle strength by isometric testing showed no differences between viltolarsen-treated participants and the CINRG DNHS external comparator control group.7RACER53 is an ongoing 48-week, phase 3 double-blind, placebo controlled, randomized clinical trial that will evaluate the efficacy of viltolarsen in ambulatory DMD patients with out-of-frame deletion mutations amenable to skipping exon 53. The study will enroll 74 boys from 4 to 8 years of age with genotypically confirmed DMD on a stable dose of corticosteroids who can walk independently without assistive devices with a time to stand of less than 10 seconds. The primary endpoint is the change from baseline to week 48 in the time to stand. Secondary outcomes include the change in time to run/walk 10 meters, change in 6MWT, change in the NSAA, change in time to climb four steps, and change in muscle force contraction measured by dyanometry.8The SKIP-NMD trial of golodirsen is a U.S.-based, blinded, placebo-controlled, dose-escalation two-part Phase I/II RCT of male patients aged six to 15 years with a DMD diagnosis and DMD gene amenable to exon 53 skipping. Patients age 6 to 15 years with stable cardiac and pulmonary function, and on a stable dose of corticosteroids for at least six months were included. Additional inclusion criteria included a baseline six-minute walk test (6MWT) of greater than 250 m, a North Star Ambulatory Assessment (NSAA) score of greater than 17 or a rise time of less than 7 seconds. In part one, 12 patients were randomized to receive once-weekly intravenous infusions at escalating doses of 4, 10, 20, 30 mg/kg of golodirsen or matching placebo for 12 weeks. Part two consists of an open-label period of all patients from part one and 13 newly recruited patients who are receiving once-weekly infusions of 30 mg/kg of golodirsen for up to 168 weeks.Part one of the SKIP-NMD trial assessed safety and tolerability. In part two, the primary endpoints are change from baseline in 6MWT at 144 weeks and change in dystrophin protein levels at 48 weeks. Secondary endpoints include drug pharmacokinetics, change from baseline in FVC percent predicted, and change from baseline in dystrophin intensity at 144 weeks.At the time of pre-planned interim analysis, data from baseline and week 48 muscle biopsies, exon 53 skipping, and dystrophin localization were available for 25 patients on golodirsen. The study is ongoing, and results for the primary efficacy endpoint of 6MWT at week 144 are not yet available. Mean baseline of dystrophin in the trial was reported to be 0.095% of normal. At 48 weeks, the mean level of dystrophin had increased to 1.019% of normal resulting in an absolute increase of 0.918% of normal (p < 0.001). A clinically meaningful change in level of dystrophin has not yet been established in humans. As such, the clinical significance of these results is not clear. Among individual patients, dystrophin levels at week 48 ranged from 0.09% to4.30%.9-11ESSENCE is an ongoing 96-week, Phase 3, double-blind, placebo controlled, randomized clinical trial that will evaluate the efficacy of golodirsen and casimersen in DMD patients with out-of-frame deletion mutations amenable to skipping exon 53 and exon 45, respectively. The study will enroll 222 boys from 7 to 13 years of age with genotypically confirmed DMD and 6MWT ≥ 300 m and ≤ 450 m. The primary endpoint is the change from baseline to week 96 in 6MWT.12Viltolarsen or golodirsen have not been studied in DMD that is not amenable to exon 53 skipping, nor in other forms of muscular dystrophy (e.g., Becker muscular dystrophy).1,6This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.Viltepso is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with Viltepso. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.1.Viltepso [package insert]. Paramus, NJ; NS Pharma, Inc, March 2021.2.Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne musculardystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol; 2010 Jan; 9(1):77 93.3.Bushby K, Finkel R, Birnkrant DJ, et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 2:implementation of multidisciplinary care. Lancet Neurol; 2010 Jan; 9(2):177-189.4.Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis,and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol.2018;17(3):251-267. doi: 10.1016/S1474-4422(18)30024.5.Exondys 51 [package insert]. Cambridge, MA: Sarepta Therapeutics, Inc, January 2022.6.Vyondys 53 [package insert]. Cambridge, MA: Sarepta Therapeutics, Inc, February 2021.7.Clemens PR, Rao VK, Connolly AM, et al. Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne musculardystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol. 2020; 26;77(8):1-10. doi:10.1001/jamaneurol.2020.2025.8.Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)https:///ct2/show/NCT04060199?term=viltolarsen&draw=2&rank=1. Accessed June 5, 2023.9.Frank DE, Mercuri E, Servais, L, et al. Golodirsen induces exon skipping leading to sarcolemmal dystrophin expression inpatients with genetic mutations amenable to exon 53 skipping. Poster presented at: Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics; April 2-6, 2019; Seattle, WA.10.Muntoni F, Frank DE, Morgan J, et al. Golodirsen induces exon skipping leading to sarcolemmal dystrophin expression inpatients with genetic mutations amenable to exon 53 skipping [abstract]. Neuromuscul Disord. 2018;28:S5. Abstract D01.11.Muntoni F, Frank DE, Sardone V, et al. SRP-4053 induces exon skipping leading to sarcolemmal dystrophin expression inDuchenne muscular dystrophy patients amenable to exon 53 skipping. Poster presented at: 22nd International Annual Congress of the World Muscle Society; October 3-7, 2017; Saint Malo, France.12.Study of SRP-4045 and SRP-4053 in DMD Patients (ESSENCE)https:///ct2/show/NCT02500381?term=golodirsen&cond=Duchenne+Muscular+Dystrophy&rank=3.Accessed June 5, 2023.13.Institute for Clinical and Economic Review (ICER). Deflazacort, eteplirsen, and golodirsen for Duchenne musculardystrophy: Effectiveness and value: Evidence Report. https:///wp-content/uploads/2020/10/Corrected_ICER_DMD-Final-Report_042222.pdf. April 22, 2022. Accessed June 5, 2023. 14.Amondys 45 [package insert]. Cambridge, MA; Sarepta Therapeutics, Inc.: March 2023.Date Summary of Changes09/01/2023 ApplicationLouisianaReplaced reference link to the state-specific policy version with instruction to refer to the state’sMedicaid clinical policySupporting InformationArchived previous policy version CS2023D0095JThis Medical Benefit Drug Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state, or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state, or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state, or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state, or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. The UnitedHealthcare Medical Benefit Drug Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.。
Tissue-Tek Cryo 3 Flex 冻剂切片仪产品说明书
Feather is a registered trademark of Feather Safety Razor Co. and is used with permission.
7
A long tradition of excellence
Known for best-in-class automation and reliability Sakura Finetek remains a privately-held company in business for over 160 years. Sakura Finetek has achieved its success and solidified its reputation by providing timely, ingenious solutions to the real challenges laboratories face on a day-to-day basis.
• Intermittent* sectioning: 1 to 99 sections or total thickness of 1 to 99 microns
* Optional features available on Disinfection (D) and Disinfection/Motorized (DM) models
1 to 99 microns in 1 microns steps
1 to 100 microns in 1 microns steps
IEC 61010-1:2010 Ed:3, IEC 61010-2-010 Ed:3, IEC 61010-2-101 Ed:2, UL 61010-1 Ed:3, CAN/CSA C22.2 61010-1:2012 Ed:3 EMC: CENELEC IEC/EN 61326-1, EMC: CANELEC IEC/EN 61326-2-6
冬斯说明书
技术参数垒块类型 403 405/407410/412415最大供应压强200毫巴（20千帕）360毫巴（36千帕） IP 等级 IP54外界温度 外界温度—15C 至+ 70 C 电磁阀DIN EN 161 , A 类，2 组电压/频率〜（AC ）50-60Hz220-230V —15腕 + 10% 〜（AC ） 50-60HZ230V —15%至 + 10%功率/需求24VA 〜（AC ）230V 20 C28VA 〜（AC ） 230V 20 C50VA 〜（AC ） 230V 20 C50VA 〜（AC ） 230V 20 C除尘装置过滤器网眼规格为 0.8mm ，不许移动气体吸发装置即可更换过滤器组件垒块由以下部分构成 1-过滤器1-气体压强开关 1- 压强稳定器 2- 电磁阀-可迅速打开的安全阀 -缓慢打开的调整阀 图1.MB DLE 405-407-410-412-415 B01 S20布置图右失（刃） 1- 法兰2- 气体压强测试点 3- 法兰固定螺丝 4- 阻尼器调节装置 5- 制动器调节装置 6- 输出装置螺母7- 用于螺母的固定螺钉（未密封的）8- 低气压开关nIT ®r V 吒毕―4248632CCn◎OGQ 0J —«B• 叮6A 8LU非必要情况下需移动六角栓，请按照第3页的指示操作。
气体吸收装置的组装气体吸收装置必须在燃烧器的左侧安装，如安装需在右侧进行时，有必要将另一侧的压强测试点移动。
（2）对于型号MB DLE 403 B01，有必要移动气压开关的位置。
（8）如气体吸收器直径与燃烧器直径不一致，就需要在两者之间安装转换器气体供应管道与气体吸收器之间的的连接，通过使用气体吸收器的法兰与将其固定起来的螺母实现（3）最好使用十字头的螺钉在任何情况下，安装阀的时候线圈不能处于朝地的一面，当完成安装后，必须检查是否存在漏气并确保气体吸收器正常工作。
压强稳定器的调整（4）使用合适的螺丝起子来固定压强调整器：顺时针方向位拧紧，逆时针方向为松开。
冬斯MB -ZR420 说明书
Meßanschluß G 1/8 nach Ventil 1, beidseitig möglich
Test point connection G 1/8 downstream of valve 1, possible on both sides
Gasflußrichtung Gas flow direction
Ausgangsflansch Output flange
Meßanschluß G 1/8 nach Ventil 2 Test point connection G 1/8 downstream of valve 2
Hydraulikbremse oder Einstellteller Hydraulic brake or setting plate
Druckabgriffe / Pressure taps
0
5
1
4 23
Einbaumaße / Dimensions / [mm]
32 4
02 pe
3
4
pa
pBr
1
2
5
pe
5
3
4
pa
pBr
1,2,3,4,5 1,2,3,4,5 1,2,3,4,5
Verschlußschraube G 1/8 G 1/8 screwed sealing plug
pmax. = 360 mbar
°C
+70
0 -15
Umgebungstemperatur Ambient temperature
-15 °C … +70 °C
冬斯GW-A5压力监测器中文说明书
26
DIN EN 175 301-803
3…6
13,5
42
12,5
1 2 3 4
1 2 3
2 pe 4 1
3 pa
4 2 pe 3 pa
3
2
1
1,3, 2 4
P L
Mp N
P L
6
7 1 2 � � 43 5
6
1
2
7
3 pe
4 pa
5 pBr 6
1 2 3 4 5 6 7
5 6
5 34
2
3
4 1
2
4…6
1
4 4 4 4
2
3 4
4
1 2 3 4
2 1
3
2 1
V1
1 2
V2
3
1,2,4 G 1/8 DIN ISO 228 3
M4
2 1 3 2 1
1 4
4 4 2 3 4 4
2
3 4
MBC-300/700/1200
1
V1
1
V2
2 3
1
1 2 3 4
� � �
� �
2
3
4
�
� � �
GW...A5 GW...A5/1
5.02
适合燃气类1, 2, 3的燃气以及其他中 性气态介质。 许可证 根据欧盟气体装置准则颁发的欧盟样 机检查证：
242 576
GW…A5 CE-0085 AO 3220 根据欧盟高压装置准则颁发的欧盟样 机检查证：
02.10
GW…A5 CE0036 按照EN 1854为“S”级。 其它重要的气体使用国家的许可证。
221 630
Thermo King SLXe 寒冷箱说明书
Fácil de seleccionarFunción de bloqueo de alta velocidadFácil de utilizarFuncionamiento eléctrico SmartPower™ (OPCIONAL)Para obtener más informacióno conocer las sesiones de tutoría,póngase en contacto con suresponsable de servicio deThermo King.La función de bloqueo de alta velocidadse utiliza, generalmente, en zonasacústicamente sensibles para reducir elruido que emite el motor diesel. Estafunción no tiene efecto alguno cuandola unidad se encuentra en modo defuncionamiento eléctrico.1. Pulse la tecla Bloqueo de alta velocidad.• Se encenderá el indicador luminosoámbar para indicar que la unidad seencuentra en modo de bloqueo dealta velocidad.2. Si vuelve a pulsar la tecla Bloqueode alta velocidad, se desactivaráesta función.1. Conecte el suministro de corriente delvoltaje apropiado al receptáculo dealimentación de la unidad.2. Pulse la tecla de ENCENDIDO paraencender la unidad.• La alarma sonora de precalentamientosonará durante 20 segundos antesde que el motor eléctrico se pongaen marcha.Visualización de los códigos de alarma1. Pulse simultáneamente y mantenga pulsadas la tecla de ENCENDIDO y la teclaREV ANT VIA.TK 61004-8-PC-ES (Vers. 0, 01/13) ©Thermo King Corporationconmutación automática de eléctrico a dieselSi la función conmutación automática de eléctrico a diesel activada estáconfigurada en SÍ, la unidad conmutará automáticamente de modo eléctrico a mododiesel cuando se retire o falle la fuente de alimentación eléctrica.conmutación automática de diesel a eléctricoSi la función conmutación automática de diesel a eléctrico activada estáconfigurada en SÍ, la unidad conmutará automáticamente de modo diesel amodo eléctrico cuando se detecte o se conecte la fuente de alimentación eléctrica.muestra en pantalla. Una vez borradastodas las alarmas, la pantalla mostraráúnicamente ceros para indicar que noexiste ningún código de alarma.• Antes de borrar cualquier alarma, deben visualizarse todas ellas.• Si una alarma no se borra, puede que todavía exista. Si la alarma no se corrige,no se borrará o puede que se vuelva a generar inmediatamente.• No es posible borrar algunas de las alarmas con la HMI.consulte el manual del operador para obtener más información en relacióncon los códigos de alarma.1. Pulse la tecla de ENCENDIDO para encender la unidad.• Aparecerán guiones tanto en la parte superior como en la parte inferior de la pantalla mientras se enciende.• A continuación, se muestranbrevemente los contadores horarios relativos al tiempo de funcionamiento.• Aparecerá la pantalla estándar mostrando la temperatura del compartimento y la del punto de consigna.• El motor diesel se precalentará y arrancará según sea necesario cuando la unidad se encuentre1. Pulse la tecla CYCLE-SENTRY/Continuo para pasar del modo CYCLE-SENTRY al modo continuo.• El indicador luminoso de color ámbar indica que la unidad está funcionando en modo CYCLE-SENTRY.• Si no hay ningún indicadorluminoso encendido, la unidad está funcionando en modo continuo.1. Pulse la tecla DESCARCH para iniciar un descarche manual.• Un indicador luminoso ámbar junto a la tecla DESCARCH indica que la unidad se encuentra en descarche.NOTA: el ciclo de descarche finaliza automáticamente cuando el serpentín delevaporador alcanza una temperatura predeterminada o cuando haya transcurrido el tiempo establecido por el temporizador de descarche. También se puede finalizar un ciclo de descarche apagando y volviendo a encender la unidad.prueba de reVisiÓn antes del ViaJe completaNOTA: la revisión antes del viaje completa debe realizarse con la unidad apagada.encendida. En las unidades equipadas con SmartPower, el motor eléctrico se pondrá en marcha si la unidad está conectada a una fuente de alimentación eléctrica.2. Pulse la tecla de APAGADO para apagar la unidad.• La unidad se apagará inmediatamente y la pantalla quedará en blanco.1. Pulse las teclas de dirección hacia ARRIBA o hacia ABAJO hasta que se muestre el punto de consigna deseado.2. Pulse la tecla ENTRAR para confirmar el nuevo punto de consigna.1. Encienda la unidad, borre todos los códigos de alarma y apague la unidad.2. Vuelva a encender la unidad y espere a que se muestren los contadores horarios del tiempo de funcionamiento de la unidad. Cuando se muestren los contadores horarios, pulse y mantenga pulsada la tecla REV ANT VIA durante 5 segundos.• Un indicador luminoso parpadeante indica que se ha iniciado la revisión antes del viaje.• Un indicador luminoso de color ámbar iluminado permanentemente indica que la revisión antes del viaje está en curso.• La prueba de revisión antes del viaje completa tarda, generalmente, entre 20 y 30 minutos.• El indicador luminoso ámbar se apagará cuando se complete la prueba de revisión antes del viaje o si se produce una alarma de apagado.prueba de reVisiÓn antes del ViaJe con el motor en FuncionamientoNOTA: la prueba de revisión antes del viaje con el motor en funcionamiento debe realizarse con la unidad en funcionamiento.1. Encienda la unidad, borre todos los códigos de alarma y permita que la unidad se ponga en marcha.2. Con la unidad en funcionamiento, pulse y mantenga pulsada la tecla REV ANT VIA durante 5 segundos.• Un indicador luminoso parpadeante indica que se ha iniciado la revisión antes del viaje.• Un indicador luminoso de color ámbar iluminado permanentemente indica que la revisión antes del viaje está en curso.• La prueba de revisión antes del viaje completa tarda, generalmente, entre 20 y 25 minutos.• El indicador luminoso ámbar se apagará cuando se complete la prueba de revisión antes del viaje o si se produce una alarma de apagado.Para detener una prueba de revisión antes del viaje en cualquier momento, pulse la tecla de APAGADO para apagar la unidad. Esta acción generará el código de alarma 28: Interrupción de la revisión antes del viaje.resultados de la prueba de reVisiÓn antes del ViaJe Superación de la prueba de revisión antes del viaje• Si la unidad supera la prueba de revisión antes del viaje, se apagará el indicador luminoso ámbar correspondiente a esta cuando finalice la prueba y la unidad seguirá funcionando según sea necesario.Fallo de la prueba de revisión antes del viaje con alarmas de corrección• Si la unidad no supera la prueba de revisión antes del viaje y se generan alarmas de corrección, aparecerá el icono de alarma cuando se produzca la condición de alarma. Seguirá realizándose la prueba de revisión antes del viaje a menos que se genere una alarma de apagado.consulte el manual del operador para obtener más información en relación con los códigos de alarma.。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
技术参数
垒块类型403 405/407 410/412 415
最大供应压强200毫巴（20千
帕）
360毫巴（36千帕）
IP等级IP54
外界温度外界温度－15℃至＋70℃电磁阀DIN EN 161，A类，2组
电压/频率～（AC）50-60Hz
220-230V
－15%至＋10%
～（AC）50-60Hz
230V
－15%至＋10%
功率/需求
24VA
～（AC）
230V
20℃
28VA
～（AC）
230V
20℃
50VA
～（AC）
230V
20℃
50VA
～（AC）
230V
20℃
除尘装置过滤器网眼规格为0.8mm,不许移动气体吸发装置即可更换过滤器
组件布置图右失（刃）
垒块由以下部分构成 1-法兰
1-过滤器 2-气体压强测试点
1-气体压强开关 3-法兰固定螺丝
1-压强稳定器 4-阻尼器调节装置
2-电磁阀 5-制动器调节装置
-可迅速打开的安全阀 6-输出装置螺母
-缓慢打开的调整阀 7-用于螺母的固定螺钉（未密封的）
图1. 8-低气压开关
MB DLE 405-407-410-412-415 B01 S20 MB DLE 403 B01 S20
气体吸收装置的组装
气体吸收装置必须在燃烧器的左侧安装，如安装需在右侧进行时，有必要将另一侧的压强测试点移动。
(2)
对于型号MB DLE 403 B01，有必要移动气压开关的位置。
（8）
如气体吸收器直径与燃烧器直径不一致，就需要在两者之间安装转换器
气体供应管道与气体吸收器之间的的连接，通过使用气体吸收器的法兰与将其固定起来的螺母实现（3）
最好使用十字头的螺钉
在任何情况下，安装阀的时候线圈不能处于朝地的一面，当完成安装后，必须检查是否存在漏气并确保气体吸收器正常工作。
压强稳定器的调整（4）
使用合适的螺丝起子来固定压强调整器：顺时针方向位拧紧，逆时针方向为松开。
当压强阀的安装达到理想效果后，盖上盖子并将电线末端用铅封好，使穿过孔间的线圈尽可能的短。
阀的调整
缓慢点火输出（阀的初始开启相位）的调整：再打开外壳（5）并按照+/—方向旋转螺钉之后进行
翻转外壳（5）可以作为调整的工具。
点火阶段中，通过操作液压制动器来控制，输出逐渐增加，在未封死螺钉（7）被
松开的情况下，通过转换螺母来调整即时输出。
输出优化
通过如下手段，第一步操作阀的开启，第二步调整压强稳定器，是可以对垒块气体吸收器的工作进行优化以获得理想的输出。
如未到到预期效果，重复以上操作步骤。
低气压开关的调整
在执行初期阶段所有有关燃烧器压强开关的调整工作后，通过调节刻度尺转盘来对气体压强开关（8）进行调整，使燃烧器处于正常输出的工作状态下。
慢慢关闭阀门直到压强（盖亚强在气体压强开关检具上测量出来）降低5-6mbar 慢慢旋转气体压强开关的把手，直到该气体压强开关以及燃烧器停止工作，完全打开阀门。
过滤器的维护
以下操作必须由技术熟练人员进行
至少每年对过滤器进行一次检查
在不移动吸收器的情况下即可对过滤器进行更换，如果过滤器经常更换，最好紧固螺丝也经常更换。
维护步骤如下：
＞关闭阀门及切断气流
＞拧开螺钉并打开外壳
＞取出旧过滤器并更换新的
＞重新盖上外壳，拧紧螺钉，但不可过紧
＞进行测试操作并检查是否漏气
线路结构（见图2）
气体吸收器出厂设置线路连接图见图2
注意事项
在启动任何工作状态前需确保电力供应被切断
对于带接线板的燃烧器，必须按照以下指示来对
吸收器连接六角栓对进移动。
＞拧开栓的螺钉并打开外壳
＞拧开接线柱螺钉并移开连接线路
＞认真按照相关操作手册的指导，将连接线路和燃烧器接线板相连接。
注意
对于RS,RLS,RS/M系列的燃烧器：必须按照燃烧器操作指示手册中的线路示意图来移动吸收器连接六角栓
气体吸收装置压强损耗
气体吸收装置压强损耗△p请见以下示意图
a=气体
n=天然气（G20）
p=丙烷（G30）
c=城市气体（G14 0）只能用于（气体用途指令90/396/EEC）所规定之外的用途，通过对压强稳定器的调整，示意图中的重要性有所变化。
Welcome To Download !!!
欢迎您的下载，资料仅供参考！。